111-LB: Oral Semaglutide vs. Sitagliptin: Efficacy by Baseline HbA1c and Background OAD in PIONEER 3

• Published in: Diabetes (New York, N.Y.) Vol. 68; no. Supplement_1
• Main Authors: ROSENSTOCK, JULIO, ALLISON, DALE C., BIRKENFELD, ANDREAS L., BLICHER, THALIA MARIE, DEENADAYALAN, SRIKANTH, KOUSHOLT, ASTRID, DAVIES, MELANIE J.
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 01-06-2019
• Subjects: Antidiabetics; Glucose; Glucose monitoring; Hemoglobin; Metformin; Sulfonylurea
• ISSN: 0012-1797; 1939-327X
• DOI: 10.2337/db19-111-LB

Exploratory analyses of PIONEER 3 (NCT02607865) assessed the efficacy (HbA1c change from baseline [BL], achievement of HbA1c <7.0%) of oral semaglutide (sema; 3, 7, or 14 mg), a novel oral GLP-1 receptor agonist, vs. sitagliptin (sita) 100 mg at week 26 by BL HbA1c and background OAD in pts with T2D uncontrolled on metformin ± sulfonylurea.
HbA1c was reduced across all BL HbA1c and OAD groups in all treatment arms; reductions were greater with higher BL HbA1c. HbA1c reductions were significantly greater with oral sema 7 and 14 mg vs. sita in all groups, except for 7 mg in the HbA1c ≤8.0% group (Figure 1). Achievement of HbA1c <7.0% was greater with oral sema 7 and 14 mg vs. sita in all groups (Figure 2).
In conclusion, oral sema 7 and 14 mg significantly improved glycemic control vs. sita across most HbA1c groups, and irrespective of background OAD use.
Disclosure
J. Rosenstock: Research Support; Self; AstraZeneca, Bristol-Myers Squibb Company, Genentech, Inc., GlaxoSmithKline plc., Lexicon Pharmaceuticals, Inc., Melior Pharmaceuticals, Inc., Bukwang Pharm. Co., Ltd., Merck & Co., Inc., Oramed Pharmaceuticals, PegBio Co., Ltd., Pfizer Inc. Other Relationship; Self; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. D.C. Allison: Advisory Panel; Self; Novo Nordisk Inc. Research Support; Self; Bayer US, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Kowa Pharmaceutical Europe Co. Ltd., Sanofi. A.L. Birkenfeld: None. T.M. Blicher: Employee; Self; Novo Nordisk A/S. S. Deenadayalan: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. A. Kousholt: Employee; Self; Novo Nordisk A/S. M.J. Davies: Advisory Panel; Self; Eli Lilly and Company, Janssen Global Services, LLC., Novo Nordisk A/S, Sanofi-Aventis, Servier. Research Support; Self; Boehringer Ingelheim International GmbH, Novo Nordisk Foundation. Speaker’s Bureau; Self; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk A/S, Sanofi-Aventis, Takeda Pharmaceutical Company Limited.
Funding
Novo Nordisk A/S